Lymphatic transport of proteins after subcutaneous administration.
about
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentPEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.Near infrared fluorescent optical imaging for nodal staging.Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrationsMicroscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imagingSubcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.Long-circulating delivery of bioactive polysaccharide from radix ophiopogonis by PEGylationPharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice.Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity.Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.Population pharmacokinetics of darbepoetin alfa in healthy subjectsMechanistic determinants of biotherapeutics absorption following SC administration.Biodistribution and Lymphatic Tracking of the Main Neurotoxin of Micrurus fulvius Venom by Molecular Imaging.Population Pharmacokinetic Modelling of FE 999049, a Recombinant Human Follicle-Stimulating Hormone, in Healthy Women After Single Ascending DosesAlbumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.Scaling pharmacodynamics from in vitro and preclinical animal studies to humans.A Helix-Stabilizing Linker Improves Subcutaneous Bioavailability of a Helical Peptide Independent of Linker Lipophilicity.Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective.Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals.Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A micePharmacokinetics and pharmacodynamics of pegfilgrastim.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools.Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.Engineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy.Clinical Decision Support Tools: The Evolution of a Revolution.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiencyDifferent pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line.Evaluation of the lethal potency of scorpion and snake venoms and comparison between intraperitoneal and intravenous injection routes.Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites.Body mass index and nonresponse to antiviral treatment in korean patients with genotype 2 and 3 chronic hepatitis C.Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection.
P2860
Q28082880-11316504-A2FC-413E-9D3B-61D805273427Q33619866-99D97571-FE54-4DD7-A94B-02D044AFD7AAQ34038991-5C6CFBB7-F991-4554-AB10-BCA14F258351Q34099832-2D8898ED-670B-46CB-B7FB-25DB4A9FDEB9Q34473944-F5E11C33-958B-4CFF-8806-263461D35368Q34614211-7A843EEB-D1C2-45F7-AC77-B84BB0030D25Q35574701-841D59A7-9F15-40C5-A6CB-1A7072796773Q35888386-6A5821B6-2466-44BA-825A-DE8E59CEF847Q35983565-D5B4C71F-323D-43BE-9CB4-9B250C0863AAQ35992509-C870FF2D-FF1B-40F8-B5B1-F172AF4CC15EQ36024876-77EFCC88-9757-4485-B14C-71653F833A38Q36065572-C5164190-FAF6-459A-8CF6-DF0A08D8F789Q36846066-5C9C7EFA-57A3-4446-8725-437EA9398A96Q36924006-8523DEC6-FC5B-45A1-838D-8F29296D320AQ36990220-00CA1B4A-93DF-44D9-8B6D-C5F8B16F6599Q37055123-F5EC0F2E-2B8E-4BEF-85E5-B3AF758E79DFQ37116075-2DCDEAEB-1078-4712-97BD-5F4F125752B1Q37207756-8481587B-61FF-4467-990D-A3ECF90767F7Q37389682-548B9241-6608-4281-8CD0-FFAC41FA594AQ37485765-E6FAE36B-CB46-43D2-9E3D-B5651E04337BQ37860299-7571242B-2B85-4524-BBA9-69E3D29E8CFDQ38072598-366D97AC-B848-4EFE-82F1-8038CAE4FD2FQ38126361-2018AA29-F7D2-471C-BEE3-1F44252DF93AQ38128342-1AA53D51-CE8C-440E-87C0-E7F441762515Q38266635-D85BFFBB-45EE-4023-9115-7BC07BEFDA02Q38364464-55CC1CD7-9EAF-434A-8B05-AEE074105D7EQ38364467-4F0E8CD6-9FDB-47B9-815F-E24B2A90AADDQ38613355-DC838BCD-F1F5-4A8A-9780-DC62806692B7Q38702792-E4964479-9B9B-433E-BCD9-FB773F00C4C4Q38714339-6E639829-C232-4B42-879E-2B169E6E6D91Q38750666-1194EAFD-4918-4F98-B9E7-A983BCBDEDABQ38822920-15537E5A-36E7-49D9-98BF-079A1C3EF7A3Q38842554-FEF3A4FC-6783-409B-9427-D3088B40D4A4Q38912246-F5DC2B30-929A-4DA8-B1F7-87AB4ECC72C4Q38997997-0ED1055E-41DB-4A1F-A5AD-B669E0E54235Q39330887-73AA0009-E46B-45E7-BA45-1E24A0809958Q39810650-7A873E59-642A-4CA5-B719-CF80A2B867AEQ41912262-8D07250A-116D-43AE-9C4D-E169E865234CQ42202021-F77B4DF5-5E18-4EDB-A1DE-10078E461488Q42284132-ACB6B9E7-28A2-49DC-924B-6145532A3EAF
P2860
Lymphatic transport of proteins after subcutaneous administration.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Lymphatic transport of proteins after subcutaneous administration.
@ast
Lymphatic transport of proteins after subcutaneous administration.
@en
type
label
Lymphatic transport of proteins after subcutaneous administration.
@ast
Lymphatic transport of proteins after subcutaneous administration.
@en
prefLabel
Lymphatic transport of proteins after subcutaneous administration.
@ast
Lymphatic transport of proteins after subcutaneous administration.
@en
P1476
Lymphatic transport of proteins after subcutaneous administration.
@en
P2093
P304
P356
10.1002/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P
P407
P577
2000-03-01T00:00:00Z